Wendy Verret

机构：Gilead Sciences (Spain), Gilead Sciences (United States)

发表论文 78 篇 · 总被引 13575 次 · h-index 28

代表论文

• Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial (2023 · The Lancet · 被引 466)
• Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). (2023 · Journal of Clinical Oncology · 被引 35)
• Health-related quality of life with sacituzumab govitecan in HR+/HER2− metastatic breast cancer in the phase III TROPiCS-02 trial (2024 · The Oncologist · 被引 16)
• 194P Safety outcomes by UGT1A1 status in the phase III TROPiCS-02 study of sacituzumab govitecan (SG) in HR+/HER2– metastatic breast cancer (mBC) (2023 · ESMO Open · 被引 9)
• Pooled safety analysis of sacituzumab govitecan (SG) in multiple solid tumor types. (2024 · Journal of Clinical Oncology · 被引 8)
• Abstract GS1-09: Sacituzumab govitecan vs chemotherapy as first therapy after endocrine therapy in HR+/HER2− (IHC 0, 1+, 2+/ISH−) metastatic breast cancer: Primary results from ASCENT-07 (2026 · Clinical Cancer Research · 被引 6)